{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:34Z","timestamp":1787797114435,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82474001, 82274023, 82373135, 82573658"],"award-info":[{"award-number":["82474001, 82274023, 82373135, 82573658"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00965-1","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:16:10Z","timestamp":1780920970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization"],"prefix":"10.1186","volume":"31","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jie","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"3","key":"965_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"965_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/cancers16040716","volume":"16","author":"MV Rojiani","year":"2024","unstructured":"Rojiani MV, Rojiani AM. Non-small cell lung cancer-tumor biology. Cancers (Basel). 2024;16(4):716.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"965_CR3","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/pharmaceutics15061604","volume":"15","author":"C Laface","year":"2023","unstructured":"Laface C, et al. The resistance to EGFR-TKIs in non-small cell lung cancer: From molecular mechanisms to clinical application of new therapeutic strategies. Pharmaceutics. 2023;15(6):1604.","journal-title":"Pharmaceutics"},{"issue":"12","key":"965_CR4","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1007\/s00432-021-03828-8","volume":"147","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wang H, He C. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. J Cancer Res Clin Oncol. 2021;147(12):3653\u201364.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"18","key":"965_CR5","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-22-1912","volume":"29","author":"JB Blaquier","year":"2023","unstructured":"Blaquier JB, et al. Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer. Clin Cancer Res. 2023;29(18):3579\u201391.","journal-title":"Clin Cancer Res"},{"key":"965_CR6","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.critrevonc.2024.104295","volume":"196","author":"A Ferro","year":"2024","unstructured":"Ferro A, et al. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Crit Rev Oncol Hematol. 2024;196:104295.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"965_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"issue":"4","key":"965_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377\u201391.","journal-title":"Nat Cancer"},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.steroids.2017.10.013","volume":"133","author":"M Taya","year":"2018","unstructured":"Taya M, Hammes SR. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and cancer: A novel potential therapeutic target. Steroids. 2018;133:102\u20137.","journal-title":"Steroids"},{"issue":"3","key":"965_CR10","doi-asserted-by":"publisher","first-page":"e70033","DOI":"10.1002\/mog2.70033","volume":"4","author":"Z Wu","year":"2025","unstructured":"Wu Z, et al. The role of Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) in tumors and other diseases. MedComm-Oncol. 2025;4(3):e70033.","journal-title":"MedComm-Oncol"},{"key":"965_CR11","first-page":"101260","volume":"53","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health West Pac. 2024;53:101260.","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"965_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard A, et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell. 2020;182(5):1232-1251.e22.","journal-title":"Cell"},{"issue":"559","key":"965_CR13","doi-asserted-by":"publisher","first-page":"eaaz4589","DOI":"10.1126\/scitranslmed.aaz4589","volume":"12","author":"MB Nilsson","year":"2020","unstructured":"Nilsson MB, et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12(559):eaaz4589.","journal-title":"Sci Transl Med"},{"issue":"14","key":"965_CR14","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1158\/0008-5472.CAN-20-3555","volume":"81","author":"Y Haga","year":"2021","unstructured":"Haga Y, et al. Host-dependent phenotypic resistance to EGFR tyrosine kinase inhibitors. Cancer Res. 2021;81(14):3862\u201375.","journal-title":"Cancer Res"},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.omtn.2020.07.027","volume":"21","author":"Y Huang","year":"2020","unstructured":"Huang Y, et al. circSETD3 contributes to acquired resistance to Gefitinib in non-small-cell lung cancer by targeting the miR-520h\/ABCG2 pathway. Mol Ther Nucleic Acids. 2020;21:885\u201399.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"965_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1055\/a-2192-0101","volume":"131","author":"V Bianco","year":"2023","unstructured":"Bianco V, Kratky D. Glycoprotein non-metastatic protein B (GPNMB): the missing link between lysosomes and obesity. Exp Clin Endocrinol Diabetes. 2023;131(12):639\u201345.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"965_CR17","doi-asserted-by":"publisher","first-page":"16103","DOI":"10.1038\/s41598-025-00793-x","volume":"15","author":"F Zhou","year":"2025","unstructured":"Zhou F, et al. SDC4 identified as an oncogenic target gene of NF-\u03baB in TNF\u03b1-induced tumor cells. Sci Rep. 2025;15(1):16103.","journal-title":"Sci Rep"},{"issue":"1","key":"965_CR18","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s12672-025-02975-5","volume":"16","author":"G Liu","year":"2025","unstructured":"Liu G, et al. Syndecan-4 promotes gastric cancer progression through activating TGF-\u03b21 induced lipid reprogramming and contributes positive loop circuits. Discov Oncol. 2025;16(1):1104.","journal-title":"Discov Oncol"},{"key":"965_CR19","doi-asserted-by":"publisher","first-page":"153515","DOI":"10.1016\/j.bbrc.2026.153515","volume":"809","author":"Y Yokoyama","year":"2026","unstructured":"Yokoyama Y, et al. SDC4 is a novel target of the KLF5 transcription factor. Biochem Biophys Res Commun. 2026;809:153515.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"965_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/eji.200838990","volume":"39","author":"JS Chung","year":"2009","unstructured":"Chung JS, et al. The DC-HIL\/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol. 2009;39(4):965\u201374.","journal-title":"Eur J Immunol"},{"issue":"11","key":"965_CR21","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.1074\/jbc.M008539200","volume":"276","author":"S Shikano","year":"2001","unstructured":"Shikano S, et al. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem. 2001;276(11):8125\u201334.","journal-title":"J Biol Chem"},{"issue":"9","key":"965_CR22","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.4049\/jimmunol.179.9.5778","volume":"179","author":"JS Chung","year":"2007","unstructured":"Chung JS, et al. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol. 2007;179(9):5778\u201384.","journal-title":"J Immunol"},{"issue":"40","key":"965_CR23","doi-asserted-by":"publisher","first-page":"25548","DOI":"10.1074\/jbc.273.40.25548","volume":"273","author":"A Horowitz","year":"1998","unstructured":"Horowitz A, Simons M. Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Calpha. J Biol Chem. 1998;273(40):25548\u201351.","journal-title":"J Biol Chem"},{"issue":"Pt 1","key":"965_CR24","first-page":"1","volume":"368","author":"MD Bass","year":"2002","unstructured":"Bass MD, Humphries MJ. Cytoplasmic interactions of syndecan-4 orchestrate adhesion receptor and growth factor receptor signalling. Biochem J. 2002;368(Pt 1):1\u201315.","journal-title":"Biochem J"},{"issue":"11","key":"965_CR25","doi-asserted-by":"publisher","first-page":"e0187094","DOI":"10.1371\/journal.pone.0187094","volume":"12","author":"A Keller-Pinter","year":"2017","unstructured":"Keller-Pinter A, et al. The phosphomimetic mutation of syndecan-4 binds and inhibits Tiam1 modulating Rac1 activity in PDZ interaction-dependent manner. PLoS ONE. 2017;12(11):e0187094.","journal-title":"PLoS ONE"},{"issue":"2","key":"965_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/cm.20007","volume":"58","author":"CA Otey","year":"2004","unstructured":"Otey CA, Carpen O. Alpha-actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton. 2004;58(2):104\u201311.","journal-title":"Cell Motil Cytoskeleton"},{"issue":"8","key":"965_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro A, Panciera T, Piccolo S. YAP\/TAZ upstream signals and downstream responses. Nat Cell Biol. 2018;20(8):888\u201399.","journal-title":"Nat Cell Biol"},{"issue":"16","key":"965_CR28","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1091\/mbc.E19-01-0027","volume":"31","author":"LM Hoffman","year":"2020","unstructured":"Hoffman LM, et al. Mechanical stress triggers nuclear remodeling and the formation of transmembrane actin nuclear lines with associated nuclear pore complexes. Mol Biol Cell. 2020;31(16):1774\u201387.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"965_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13287-024-03884-0","volume":"15","author":"X Meng","year":"2024","unstructured":"Meng X, et al. The cytoskeleton dynamics-dependent LINC complex in periodontal ligament stem cells transmits mechanical stress to the nuclear envelope and promotes YAP nuclear translocation. Stem Cell Res Ther. 2024;15(1):284.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"965_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s10020-024-00934-4","volume":"30","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients. Mol Med. 2024;30(1):209.","journal-title":"Mol Med"},{"issue":"13","key":"965_CR31","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.3390\/cancers13133322","volume":"13","author":"A Keller-Pinter","year":"2021","unstructured":"Keller-Pinter A, et al. Syndecan-4 in tumor cell motility. Cancers (Basel). 2021;13(13):3322.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"965_CR32","first-page":"126","volume":"8","author":"K Pfisterer","year":"2017","unstructured":"Pfisterer K, Jayo A, Parsons M. Control of nuclear organization by F-actin binding proteins. Nucleus (Austin Tex). 2017;8(2):126\u201333.","journal-title":"Nucleus (Austin Tex)"},{"issue":"2","key":"965_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70073","volume":"6","author":"F Paganelli","year":"2025","unstructured":"Paganelli F, et al. At the nucleus of cancer: how the nuclear envelope controls tumor progression. MedComm. 2025;6(2):e70073.","journal-title":"MedComm"},{"issue":"6","key":"965_CR34","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.cell.2017.10.008","volume":"171","author":"A Elosegui-Artola","year":"2017","unstructured":"Elosegui-Artola A, et al. Force triggers YAP nuclear entry by regulating transport across nuclear pores. Cell. 2017;171(6):1397-1410 e14.","journal-title":"Cell"},{"issue":"11","key":"965_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.tibs.2010.05.010","volume":"35","author":"M Sudol","year":"2010","unstructured":"Sudol M, Harvey KF. Modularity in the Hippo signaling pathway. Trends Biochem Sci. 2010;35(11):627\u201333.","journal-title":"Trends Biochem Sci"},{"issue":"10","key":"965_CR36","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.3390\/cells10102624","volume":"10","author":"LF Flores","year":"2021","unstructured":"Flores LF, et al. Nuclear dynamics and chromatin structure: implications for pancreatic cancer. Cells. 2021;10(10):2624.","journal-title":"Cells"},{"issue":"1","key":"965_CR37","doi-asserted-by":"publisher","first-page":"10030","DOI":"10.1038\/s41467-025-65224-x","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, et al. Regulation of lipoprotein processing by GPNMB in foamy macrophages: potential therapeutic targets for atherosclerosis. Nat Commun. 2025;16(1):10030.","journal-title":"Nat Commun"},{"key":"965_CR38","doi-asserted-by":"publisher","first-page":"105764","DOI":"10.1016\/j.humpath.2025.105764","volume":"157","author":"H Li","year":"2025","unstructured":"Li H, et al. Examination of the histogenesis of epithelial cysts in angiomyolipoma with epithelial cysts (AMLEC) using GPNMB and TSC2 immunostains. Hum Pathol. 2025;157:105764.","journal-title":"Hum Pathol"},{"key":"965_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12964-015-0099-5","volume":"13","author":"M Gutknecht","year":"2015","unstructured":"Gutknecht M, et al. The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. Cell Commun Signal. 2015;13:19.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"965_CR40","doi-asserted-by":"publisher","first-page":"e71616","DOI":"10.1096\/fj.202504363R","volume":"40","author":"EM de Oliveira Furtado","year":"2026","unstructured":"de Oliveira Furtado EM, et al. Lack of GPNMB is associated with altered lipid and glucose metabolism and disrupted diurnal hepatic glycogen regulation. FASEB J. 2026;40(6):e71616.","journal-title":"FASEB J"},{"issue":"1","key":"965_CR41","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1038\/s41598-022-10522-3","volume":"12","author":"M Suda","year":"2022","unstructured":"Suda M, et al. Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells. Sci Rep. 2022;12(1):6522.","journal-title":"Sci Rep"},{"key":"965_CR42","doi-asserted-by":"publisher","first-page":"112429","DOI":"10.1016\/j.cellsig.2026.112429","volume":"142","author":"X Zhang","year":"2026","unstructured":"Zhang X, et al. Glycoprotein non-metastatic melanoma protein B promotes pyroptosis of macrophages induced by homocysteine associated with the upregulation of the NOX-2\/ NF-\u03baB signaling pathway. Cell Signal. 2026;142:112429.","journal-title":"Cell Signal"},{"issue":"1","key":"965_CR43","doi-asserted-by":"publisher","first-page":"12171","DOI":"10.1038\/s41598-021-91588-3","volume":"11","author":"YH Huang","year":"2021","unstructured":"Huang YH, et al. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Sci Rep. 2021;11(1):12171.","journal-title":"Sci Rep"},{"issue":"13","key":"965_CR44","doi-asserted-by":"publisher","first-page":"e187684","DOI":"10.1172\/jci.insight.187684","volume":"10","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Glycoprotein NMB mediates bidirectional GSC-TAM interactions to promote tumor progression. JCI Insight. 2025;10(13):e187684.","journal-title":"JCI Insight"},{"issue":"1","key":"965_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s43856-025-00786-x","volume":"5","author":"JS Chung","year":"2025","unstructured":"Chung JS, et al. Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade. Commun Med (Lond). 2025;5(1):79.","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"965_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/ol.2021.13154","volume":"23","author":"JP Zhai","year":"2022","unstructured":"Zhai JP, et al. GPNMB overexpression is associated with extensive bone metastasis and poor prognosis in renal cell carcinoma. Oncol Lett. 2022;23(1):36.","journal-title":"Oncol Lett"},{"issue":"16","key":"965_CR47","doi-asserted-by":"publisher","first-page":"16238","DOI":"10.18632\/aging.103646","volume":"12","author":"K Yao","year":"2020","unstructured":"Yao K, et al. Prognostic values of GPNMB identified by mining TCGA database and STAD microenvironment. Aging (Albany NY). 2020;12(16):16238\u201354.","journal-title":"Aging (Albany NY)"},{"issue":"5","key":"965_CR48","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/cas.14872","volume":"112","author":"CL Han","year":"2021","unstructured":"Han CL, et al. N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC. Cancer Sci. 2021;112(5):1911\u201323.","journal-title":"Cancer Sci"},{"issue":"12","key":"965_CR49","doi-asserted-by":"publisher","first-page":"13932","DOI":"10.18632\/oncotarget.7323","volume":"7","author":"MO Oyewumi","year":"2016","unstructured":"Oyewumi MO, et al. Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells. Oncotarget. 2016;7(12):13932\u201344.","journal-title":"Oncotarget"},{"key":"965_CR50","doi-asserted-by":"publisher","first-page":"1642253","DOI":"10.3389\/fonc.2025.1642253","volume":"15","author":"P Han","year":"2025","unstructured":"Han P, et al. Noninvasive prediction of EGFR 19Del and 21L858R subtypes in lung adenocarcinoma: a comparative study of logistic regression and decision tree models. Front Oncol. 2025;15:1642253.","journal-title":"Front Oncol"},{"key":"965_CR51","doi-asserted-by":"publisher","first-page":"869390","DOI":"10.3389\/fonc.2022.869390","volume":"12","author":"PC Hsieh","year":"2022","unstructured":"Hsieh PC, et al. Comparison of T790M acquisition after treatment with first- and second-generation tyrosine-kinase inhibitors: a systematic review and network meta-analysis. Front Oncol. 2022;12:869390.","journal-title":"Front Oncol"},{"issue":"7","key":"965_CR52","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","volume":"19","author":"M Borgeaud","year":"2024","unstructured":"Borgeaud M, et al. Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review. J Thorac Oncol. 2024;19(7):973\u201383.","journal-title":"J Thorac Oncol"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00965-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00965-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00965-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:00:18Z","timestamp":1787796018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00965-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00965-1","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee board of the First Affiliated Hospital of Chongqing Medical University (approval no. 2022-K432), and was registered with the Chinese Clinical Trial Registry (no. ChiCTR2200066004). All animal studies were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Animal Ethics and Experimental Committee of Chongqing Medical University. Informed consent was obtained from all subjects involved in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"133"}}